Doctors Blast Rosy Research For Medtronic Bone Device

Law360, New York (June 28, 2011, 9:19 PM EDT) -- The authors of 13 industry-sponsored studies on Medtronic Inc.'s bone-growth device Infuse downplayed serious risks related to the product and failed to adequately — if at all — disclose their financial ties with the manufacturer, a study published Tuesday said.

A review of the industry-sponsored studies by The Spine Journal shows that risks of side effects were 10 to 50 times higher than originally reported in the 13 trials. Many authors of the 13 studies involving 780 patients had a financial association with the Infuse manufacturer,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.